Inovio Pharma (INO) Misses Q2 EPS by 14c

Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.39), $0.14 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $273 thousand versus the consensus estimate of $1.21 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• Securitize Corp (SECZ) PT Lowered to $10 at Benchmark as Stock Plummets Post Q2 Earnings